DIHYDROERGOTAMINE MESYLATE Drug Patent Profile
✉ Email this page to a colleague
When do Dihydroergotamine Mesylate patents expire, and what generic alternatives are available?
Dihydroergotamine Mesylate is a drug marketed by Gland Pharma Ltd, Hikma, Hikma Pharms, Padagis Us, Provepharm Sas, Sagent Pharms Inc, Amneal, Cipla, and Rubicon. and is included in ten NDAs.
The generic ingredient in DIHYDROERGOTAMINE MESYLATE is dihydroergotamine mesylate. There are six drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the dihydroergotamine mesylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Dihydroergotamine Mesylate
A generic version of DIHYDROERGOTAMINE MESYLATE was approved as dihydroergotamine mesylate by PADAGIS US on April 28th, 2003.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DIHYDROERGOTAMINE MESYLATE?
- What are the global sales for DIHYDROERGOTAMINE MESYLATE?
- What is Average Wholesale Price for DIHYDROERGOTAMINE MESYLATE?
Summary for DIHYDROERGOTAMINE MESYLATE
| US Patents: | 0 |
| Applicants: | 9 |
| NDAs: | 10 |
| Finished Product Suppliers / Packagers: | 7 |
| Raw Ingredient (Bulk) Api Vendors: | 48 |
| Clinical Trials: | 16 |
| Patent Applications: | 1,250 |
| Drug Prices: | Drug price information for DIHYDROERGOTAMINE MESYLATE |
| What excipients (inactive ingredients) are in DIHYDROERGOTAMINE MESYLATE? | DIHYDROERGOTAMINE MESYLATE excipients list |
| DailyMed Link: | DIHYDROERGOTAMINE MESYLATE at DailyMed |
Recent Clinical Trials for DIHYDROERGOTAMINE MESYLATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Ache Laboratorios Farmaceuticos S.A. | Phase 3 |
| Xijing Hospital | Phase 2/Phase 3 |
| Satsuma Pharmaceuticals, Inc. | Phase 3 |
Pharmacology for DIHYDROERGOTAMINE MESYLATE
| Drug Class | Ergotamine Derivative |
Medical Subject Heading (MeSH) Categories for DIHYDROERGOTAMINE MESYLATE
Anatomical Therapeutic Chemical (ATC) Classes for DIHYDROERGOTAMINE MESYLATE
US Patents and Regulatory Information for DIHYDROERGOTAMINE MESYLATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gland Pharma Ltd | DIHYDROERGOTAMINE MESYLATE | dihydroergotamine mesylate | INJECTABLE;INJECTION | 215623-001 | Aug 18, 2023 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Amneal | DIHYDROERGOTAMINE MESYLATE | dihydroergotamine mesylate | SPRAY, METERED;NASAL | 214105-001 | Jan 4, 2022 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Padagis Us | DIHYDROERGOTAMINE MESYLATE | dihydroergotamine mesylate | INJECTABLE;INJECTION | 040475-001 | Apr 28, 2003 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Cipla | DIHYDROERGOTAMINE MESYLATE | dihydroergotamine mesylate | SPRAY, METERED;NASAL | 212907-001 | May 20, 2020 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Hikma | DIHYDROERGOTAMINE MESYLATE | dihydroergotamine mesylate | INJECTABLE;INJECTION | 040453-001 | Jun 9, 2003 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Hikma Pharms | DIHYDROERGOTAMINE MESYLATE | dihydroergotamine mesylate | INJECTABLE;INJECTION | 206621-001 | Sep 15, 2017 | AP | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Sagent Pharms Inc | DIHYDROERGOTAMINE MESYLATE | dihydroergotamine mesylate | INJECTABLE;INJECTION | 207264-001 | Jul 11, 2018 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
